Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43851   clinical trials with a EudraCT protocol, of which   7283   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2016-004754-15
    Sponsor's Protocol Code Number:3152-201-002
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Prematurely Ended
    Date on which this record was first entered in the EudraCT database:2017-05-29
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2016-004754-15
    A.3Full title of the trial
    Open-label Rollover Study of Cenicriviroc for the Treatment of Liver Fibrosis in Adult Subjects with Nonalcoholic Steatohepatitis (NASH)
    Estudio de continuación abierto de cenicriviroc para el tratamiento de la fibrosis hepática en pacientes adultos con esteatohepatitis no alcohólica (EHNA).
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A study to investigate the long-term safety of the drug Cenicriviroc in people with liver disease.
    Estudio para investigar la seguridad a largo plazo del fármaco Cenicriviroc en personas con enfermedad hepatica.
    A.4.1Sponsor's protocol code number3152-201-002
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorTobira Therapeutics, Inc., a subsidiary of Allergan plc
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportTobira Therapeutics, Inc., a subsidiary of Allergan plc
    B.4.2CountryUnited States
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationTobira Therapeutics, a subsidiary of Allergan plc
    B.5.2Functional name of contact pointKarl Trass (Regulatory Affairs)
    B.5.3 Address:
    B.5.3.1Street Address701 Gateway Blvd, Suite 300
    B.5.3.2Town/ citySouth San Francisco
    B.5.3.3Post codeCA 94080
    B.5.3.4CountryUnited States
    B.5.4Telephone number+1650878 6728
    B.5.5Fax number+1650741 6629
    B.5.6E-mailKarl.Trass@allergan.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameCenicriviroc
    D.3.2Product code CVC
    D.3.4Pharmaceutical form Tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCENICRIVIROC MESYLATE
    D.3.9.1CAS number 497223-25-3
    D.3.9.2Current sponsor codeCENICRIVIROC
    D.3.9.3Other descriptive nameTBR-652
    D.3.9.4EV Substance CodeSUB180705
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number150
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Liver fibrosis in Subjects with Nonalcoholic Steatohepatitis
    fibrosis hepatica en pacientes con esteatohepatitis no alcohólica
    E.1.1.1Medical condition in easily understood language
    Fatty Liver where the cells in the liver have abnormal fat built-up and
    built-up of scar tissue in the liver.
    Higado graso donde las celulas del higado tienen grasa anormal acumulada y tejido cicatirzado acumulado en el higado
    E.1.1.2Therapeutic area Diseases [C] - Nutritional and Metabolic Diseases [C18]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10053219
    E.1.2Term Non-alcoholic steatohepatitis
    E.1.2System Organ Class 10019805 - Hepatobiliary disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this study is to provide open-label treatment with CVC to subjects who have previously participated in CVC studies.
    El objetivo principal de este studio es proporcionar tratamiento abierto con CVC a pacientes que hayan participado previamente en estudios de CVC.
    E.2.2Secondary objectives of the trial
    The secondary objective of this study is to assess the long-term safety of continued treatment with CVC for subjects who have previously participated in CVC studies.
    El objetivo secundario de este studio es evaluar la seguridad a largo plazo del tratamiento continuado con CVC para pacientes que hayan participado previamente en estudios de dicho fármaco.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    For a subject to be eligible for participation in this study, all of the following criteria must apply.

    1. Successfully completed both Treatment Period 1 and Treatment Period 2, per protocol, of the CENTAUR study (652-2-203), including a Year 2 liver biopsy
    2. Must provide a signed written informed consent form
    3. Females of child-bearing potential and males participating in the study must agree to use at least 2 approved barrier methods of contraception throughout the duration of the study and for 3 months after stopping study drug. Females who are postmenopausal must have documentation of cessation of menses for ≥ 12 months and serum follicle stimulating hormone (FSH) ≥ 30 mU/mL
    1.Finalización con éxito, tanto del periodo de tratamiento 1 como del periodo de tratamiento 2, del estudio CENTAUR (652-2-203), incluyendo una biopsia de hígado en el año 2
    2.Los pacientes deberán firmar un formulario de consentimiento informado
    3.Las mujeres con posibilidad de quedar embarazadas y los hombres que participen en el estudio deben estar de acuerdo en utilizar al menos 2 métodos anticonceptivos de barrera aprobados a lo largo de la duración del estudio y durante los 3 meses siguientes a la interrupción del fármaco del estudio. Las mujeres postmenopáusicas deben tener registro de que el cese de la menstruación tuvo lugar hace 12 meses o más y presentar unos niveles de hormona foliculoestimulante (FSH) en suero ≥ 30 mUI/ml.
    E.4Principal exclusion criteria
    A subject will not be eligible for participation in this study if any of the following criteria apply.
    1. Any clinically significant change in the subject’s medical history or condition which, in the opinion of the investigator, would preclude administration of open-label CVC, including laboratory tests
    2. Prior or planned liver transplantation
    3. Other known causes of chronic liver disease, such as the following:
    • Alcoholic liver disease
    • Primary biliary cirrhosis
    • Primary sclerosing cholangitis
    • Autoimmune hepatitis
    • Wilson’s disease, hemochromatosis, or iron overload
    • Alpha-1-antitrypsis (A1AT) deficiency
    4. Females who are pregnant or breastfeeding
    5. Any other clinically significant disorders or prior therapy that, in the opinion of the investigator, would make the subject unsuitable for the study or unable to comply with the dosing and protocol requirements.
    1.Cualquier cambio clínicamente significativo en los antecedentes médicos o la enfermedad del paciente que, en opinión del investigador, impida la administración de CVC sin enmascaramiento, incluyendo las pruebas de laboratorio
    2.Trasplante hepático previo o previsto
    3.Otras causas conocidas de enfermedad hepática crónica, como las siguientes:
    •Enfermedad alcohólica del hígado
    •Cirrosis biliar primaria
    •Colangitis esclerosante primaria
    •Hepatitis autoinmunitaria
    •Enfermedad de Wilson, hemocromatosis o sobrecarga de hierro
    •Déficit de alfa-1-antitripsina (A1AT)
    4.Mujeres embarazadas o que están amamantando
    5.Cualquier otro trastorno clínicamente significativo o tratamiento anterior que, en opinión del investigador, haga al paciente no apto para el estudio o incapaz de cumplir con los requisitos de la administración y el protocolo.
    E.5 End points
    E.5.1Primary end point(s)
    Long-term safety assessment of CVC administration
    Evaluar la seguridad a largo plazo de la administracion de CVC
    E.5.1.1Timepoint(s) of evaluation of this end point
    Once Cenicriviroc is commercially available or if development is discontinued
    Una vez este disponible Cenicriviroc comercilmente o si el desarrollo es discontinuado
    E.5.2Secondary end point(s)
    Safety assessments including adverse events, hematology profile, chemistry profile, coagulation profile and serum chemistry
    Evaluaciones de seguridad incluyendo acontecimientos adversos, perfil hematologico, perfil quimico, perfil de coagulacion y quimica en suero
    E.5.2.1Timepoint(s) of evaluation of this end point
    At baseline, and every 3 months thereafter until study discontinued
    Al inicio, y cada 3 meses hasta discontinuacion del estudio
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy No
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned4
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA28
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Belgium
    France
    Germany
    Hong Kong
    Italy
    Poland
    Spain
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    When the drug product becomes commercially available or if the study is discontinued by the Sponsor
    cuando el fármaco este comercialmente disponible or si el estuio es discontinuado por el promotor
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years6
    E.8.9.1In the Member State concerned months0
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years6
    E.8.9.2In all countries concerned by the trial months0
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 160
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 40
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state9
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 83
    F.4.2.2In the whole clinical trial 200
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    CVC treatment will continue to be provided until it is commercially available or if development is terminated, as applicable.
    El tratamiento con CVC seguirá siendo proporcionado hasta que este comercialmente disponible o si su desarrollo es terminado, como aplique.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2017-07-27
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2017-07-26
    P. End of Trial
    P.End of Trial StatusPrematurely Ended
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Apr 20 03:22:41 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA